

PROFILE

Proximagen is a biotechnology company committed to developing novel drugs and innovative new treatments for patients suffering from disorders of the central nervous system (CNS).

The Company's priority therapeutic areas are Parkinson's disease, epilepsy, cognition and neuropathic pain.

Proximagen currently has one of the strongest balance sheets of any biotech company in Europe and is backed by blue chip institutional and corporate investors. Based in London, UK, Proximagen also has research facilities near Cambridge.

OUR APPROACH TO BUSINESS

We are taking a flexible approach to how far we develop our programmes before partnering or otherwise commercialising them. In taking these decisions, we are mindful of a number of factors, including development risk, the progress of competitor programmes, our financial position and our belief that the retention of marketing rights in certain territories is an important long-term value driver for the Company.

PIPELINE

We are building our pipeline to ensure a broad range of programmes at different stages of development. If you are interested in our pipeline or have programmes for partnering in our priority therapeutic areas, particularly in late-pre-clinical or clinical stage development, please call our Head of Business Development, Tim Sparey, on +44 20 7400 7700.

OUR OBJECTIVE & STRATEGY

Proximagen's objective is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS. To achieve this, the Company has identified five strategic priorities that we believe will help us achieve our objective:

- 1 Science first** We continue to expand our pipeline within the area of CNS through acquisition, in-licensing and partnering of programmes founded on strong scientific evidence.
- 2 Building relationships** We will look to build closer scientific and commercial relationships with 'Big Pharma' in our specialist areas.
- 3 Marketing rights** In the short- to medium-term we plan to develop our programmes to a value inflection point and then outlicense, preferably retaining rights in certain territories.
- 4 Balanced risk** We take an innovative approach to structuring deals and aim to align consideration with success wherever possible.
- 5 Cost elimination** We aim to reduce duplicated costs through sector consolidation and integration, and therefore produce more for less.

PHARMACEUTICAL PARTNERS

H. Lundbeck A/S

Upsher-Smith Laboratories



Proximagen's Pipeline	Lead Op.	Pre-clinical	Phase 1	Phase 2	Phase 3	Partner
EPILEPSY						
Tonabersat <i>Epilepsy in refractive patients</i>					Upsher-Smith	EU
Naluzotan <i>Epilepsy in refractive patients</i>					National Institutes of Health	Global
COGNITION						
Sabcomeline <i>Cognition in schizophrenia</i>					BCI	M/R
α7 PAM <i>Cognition in schizophrenia and Alzheimer's</i>					GSK	Global
5HT6 <i>Cognition in Parkinson's disease</i>						Global
PARKINSON'S DISEASE						
PRX1 <i>L-DOPA prodrug</i>					Upsher-Smith	M/R
D1 PAM <i>D1 Positive Allosteric Modulators</i>					GSK	Global
INFLAMMATION & NEUROINFLAMMATION						
VAP-1 <i>Rheumatoid arthritis</i>						Global
PAR-2 (IBD) <i>Ulcerative colitis</i>						Global
GPCR <i>Renal inflammation</i>						Global
PAR-2 (derm) <i>Atopic dermatitis</i>						Global
TrkA <i>Inflammatory pain</i>						Global
CANCER						
SSAO <i>Disease progression</i>						Global
CXCR4 <i>Glioblastoma multiforme</i>						Global
WEIGHT MANAGEMENT						
PRX00933 <i>Obesity and diabetes</i>						Global

Contact:

3rd Floor
91-93 Farringdon Road
London EC1M 3LN
T: +44 (0)20 7400 7700
F: +44 (0)20 7831 5387
E: info@proximagen.com
www.proximagen.com

Directors:

Peter Allen *Non-executive Chairman*
Kenneth Mulvany *Chief Executive Officer*
James Hunter *Finance Director*
Jackie Hunter *Non-executive Director*
Michael Ashton *Non-executive Director*

Sector:

Pharmaceuticals & Biotechnology

Stock Listing:

LSE AIM: PRX

Issued Share Capital:

63,119,601 Ordinary 1p Shares